Table 4.
Changes in heart failure medication and lipid lowering therapy during follow-up
| Baseline | Month 4 | Month 8 | Month 12 | P for trend* | |
|---|---|---|---|---|---|
| N = 12 | N = 12 | N = 11 | N = 12 | ||
| ACEi /ARB, n (%) | 6 (50) | 5 (42) | 6 (55) | 4 (33) | 1.0 |
| ARNI, n (%) | 5 (42) | 7 (58) | 5 (45) | 8 (67) | 0.19 |
| Betablocker, n (%) | 10 (83) | 10 (83) | 9 (82) | 11 (92) | 1.0 |
| MRA, n (%) | 8 (67) | 8 (67) | 7 (64) | 8 (67) | N.A |
| Ivabradine, n (%) | 2 (17) | 3 (25) | 3 (27) | 3 (25) | 1.0 |
| Diuretics, n (%) | 6 (50) | 7 (58) | 5 (45) | 6 (50) | 0.56 |
| Lipid lowering drug, n (%) | 5 (42) | 5 (42) | 5 (45) | 5 (42) | N.A |
| OMT, n (%) | 10 (83) | 12 (100) | 11 (100) | 12 (100) | 0.35 |
*Page’s linear trend test. N.A. Page test not applicable
ACEi/ARB, angiotensin converting enzyme inhibitor or angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor, MRA mineralocorticoid receptor blocker, OMT optimal medical therapy